Insight, China's Pharmaceutical Industry

Zhongsheng Pharma’s Onradivir (Anruiwei) Receives NMPA Review Acceptance for Pediatric Influenza A Indication – Phase III Data Shows Favorable Efficacy vs. Tamiflu

Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced that China’s National Medical Products Administration (NMPA)...

Company Drug

Huadong Medicine Receives NMPA Approval for HDM2017 ADC Trial in Colorectal Cancer – Cadherin 17-Targeting Therapy Shows Broad Solid Tumor Potential

Fineline Cube May 14, 2026

Huadong Medicine Co., Ltd. (SHE: 000963) announced it has received clinical trial approval from China’s...

Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196) announced a strategic licensing agreement with South...

Company Drug

Shanghai Henlius Biotech Doses First Patient in Phase I Trial of HLX97 – Novel KAT6A/B Inhibitor for Advanced Solid Tumors

Fineline Cube May 14, 2026

Shanghai Henlius Biotech Inc. (HKG: 2696) announced the dosing of the first patient in a...

Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026

Merck & Co., Inc. (MSD; NYSE: MRK) has established separate strategic partnerships with four leading...

Company Drug

Eli Lilly Reports Long-Term Weight Loss Maintenance with Foundayo and Lower-Dose Zepbound in Phase 3 Trials

Fineline Cube May 13, 2026

Eli Lilly and Company (NYSE: LLY) announced on May 12, 2026, detailed results from two...

Company

Legend Biotech Reports 56% Q1 Revenue Growth to $305M, Driven by Carvykti Sales Surge and J&J Milestone Payment

Fineline Cube May 13, 2026

Legend Biotech Corporation (NASDAQ: LEGN) reported first-quarter 2026 revenue of USD 305 million, representing 56%...

Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026

Shanghai Immunocan Biotech Co., Ltd. announced the successful completion of a RMB 250 million (USD...

Others

Sichuan Kelun-Biotech Receives NMPA Approval for ITGB6-Targeted ADC SKB105 in Advanced Solid Tumors Following Crescent Biopharma Licensing Deal

Fineline Cube May 13, 2026

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced it has received clinical approval from China’s...

Company Deals

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Fineline Cube May 13, 2026

Shenzhen Weiguang Biological Products Co., Ltd. (SHE: 002880), a China-based blood products manufacturer, announced plans...

Company Deals

Cellular Intelligence Acquires Global Rights to Novo Nordisk’s Parkinson’s Cell Therapy Program, Plans AI-Driven Acceleration

Fineline Cube May 13, 2026

Cellular Intelligence announced on May 11, 2026, that it has acquired global rights to Novo...

Others

Porton Advanced Solutions and Dark Horse Consulting Forge Strategic Alliance to Accelerate Global Cell and Gene Therapy Development

Fineline Cube May 13, 2026

Porton Advanced Solutions and Dark Horse Consulting Group (“DHCG”) announced on May 12, 2026, the...

Company Drug

Servier’s B7-H4 ADC Emiltatug Ledadotin Receives FDA Breakthrough Therapy Designation for Advanced Adenoid Cystic Carcinoma

Fineline Cube May 13, 2026

Servier announced on May 12, 2026, that the U.S. Food and Drug Administration (FDA) has...

Company Drug

ImmuneOnco Receives NMPA Approval for IMM0306 Clinical Study in Primary Sjögren’s Syndrome, Expanding Dual-Target Bispecific Platform

Fineline Cube May 13, 2026

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (HKG: 1541) announced it has received clinical approval from China’s...

Others

Bayer Reports 4.1% Q1 Sales Growth to €13.4B, with Mixed Pharmaceutical Performance Amid IRA Impact and Generic Competition

Fineline Cube May 13, 2026

Bayer AG (ETR: BAYN) reported first-quarter 2026 group sales of €13.405 billion (USD 15.73 billion),...

Company Deals

Boehringer Ingelheim Secures Global Rights to Immunitas’ First-in-Class Antibody Program for Chronic Inflammatory Diseases in €407.5M Deal

Fineline Cube May 13, 2026

Boehringer Ingelheim (“BI”) and Immunitas Therapeutics announced on May 12, 2026, a global licensing agreement...

Company Medical Device

Roche Secures CE Mark for Elecsys pTau217 Blood Test, First Single-Assay Alzheimer’s Diagnostic with Amyloid Pathology Detection

Fineline Cube May 13, 2026

Roche AG (SWX: ROP, OTCMKTS: RHHBY) announced on May 12, 2026, that it has received...

Company Drug

Alphamab Oncology Initiates Phase II Trial of Subcutaneous Co-Formulation JSKN033 in First-Line Advanced Cervical Cancer

Fineline Cube May 13, 2026

Alphamab Oncology (HKG: 9966) announced the initiation of a Phase II clinical study for its...

Company Drug

Bio-Thera’s CD25-Targeted ADC BAT8013 Receives NMPA Approval for Advanced Solid Tumor Clinical Studies in China

Fineline Cube May 13, 2026

Bio-Thera Solutions Ltd. (SHA: 688177) announced that its CD25-targeted antibody drug conjugate (ADC) BAT8013 has...

Company Drug

Sichuan Biokin’s Bispecific ADC Iza-Bren Receives NMPA Approval for NSCLC Clinical Study in China

Fineline Cube May 13, 2026

Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its bispecific antibody-drug conjugate (ADC) izalontamab...

Insight, China's Pharmaceutical Industry

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Zhongsheng Pharma’s Onradivir (Anruiwei) Receives NMPA Review Acceptance for Pediatric Influenza A Indication – Phase III Data Shows Favorable Efficacy vs. Tamiflu

Huadong Medicine Receives NMPA Approval for HDM2017 ADC Trial in Colorectal Cancer – Cadherin 17-Targeting Therapy Shows Broad Solid Tumor Potential

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Shanghai Henlius Biotech Doses First Patient in Phase I Trial of HLX97 – Novel KAT6A/B Inhibitor for Advanced Solid Tumors

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Eli Lilly Reports Long-Term Weight Loss Maintenance with Foundayo and Lower-Dose Zepbound in Phase 3 Trials

Legend Biotech Reports 56% Q1 Revenue Growth to $305M, Driven by Carvykti Sales Surge and J&J Milestone Payment

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Sichuan Kelun-Biotech Receives NMPA Approval for ITGB6-Targeted ADC SKB105 in Advanced Solid Tumors Following Crescent Biopharma Licensing Deal

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Cellular Intelligence Acquires Global Rights to Novo Nordisk’s Parkinson’s Cell Therapy Program, Plans AI-Driven Acceleration

Porton Advanced Solutions and Dark Horse Consulting Forge Strategic Alliance to Accelerate Global Cell and Gene Therapy Development

Servier’s B7-H4 ADC Emiltatug Ledadotin Receives FDA Breakthrough Therapy Designation for Advanced Adenoid Cystic Carcinoma

ImmuneOnco Receives NMPA Approval for IMM0306 Clinical Study in Primary Sjögren’s Syndrome, Expanding Dual-Target Bispecific Platform

Bayer Reports 4.1% Q1 Sales Growth to €13.4B, with Mixed Pharmaceutical Performance Amid IRA Impact and Generic Competition

Boehringer Ingelheim Secures Global Rights to Immunitas’ First-in-Class Antibody Program for Chronic Inflammatory Diseases in €407.5M Deal

Roche Secures CE Mark for Elecsys pTau217 Blood Test, First Single-Assay Alzheimer’s Diagnostic with Amyloid Pathology Detection

Alphamab Oncology Initiates Phase II Trial of Subcutaneous Co-Formulation JSKN033 in First-Line Advanced Cervical Cancer

Bio-Thera’s CD25-Targeted ADC BAT8013 Receives NMPA Approval for Advanced Solid Tumor Clinical Studies in China

Sichuan Biokin’s Bispecific ADC Iza-Bren Receives NMPA Approval for NSCLC Clinical Study in China

You Missed

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030

Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins